Editor's Pick
The Delta variant of SARS-CoV-2 has boosted COVID-19 testing, but the severity of the coming flu season and the need for combo tests remain unpredictable.
IVDÂ company executives noted that the acceptance and acceleration of decentralized care models have increased, enabling more effective testing for many conditions.
According to industry insiders, the UK has the chance to set new policies that will both keep the domestic IVD market safe, while keeping the country internationally competitive.
The technology has been licensed by MGeneRx, which plans to commercialize it in the US first, then expand to low- and middle-income countries.
Developed by researchers at the National Institutes of Health, the method could reduce the cost of sample prep by a factor of eight.